What is the current Transthyretin Amyloidosis Treatment market size?

The Transthyretin Amyloidosis Treatment market size was valued at approximately USD 1.2 billion in 2023, driven by rising prevalence and advanced therapies.

What is the future outlook for market growth?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by innovation in gene therapy and increased R&D investments.

What are the key drivers of this market?

Key drivers include rising awareness, improved diagnostic tools, and the approval of novel therapies like RNAi-based treatments.

What challenges hinder market expansion?

High treatment costs, limited patient access in emerging markets, and adverse drug reactions are major challenges.

Which regions are leading the market?

North America dominates due to early adoption of therapies, followed by Europe, while Asia-Pacific shows high growth potential.

Who are the top companies in this space?

Leading firms include Alnylam Pharmaceuticals, Pfizer, Ionis Pharmaceuticals, and Akcea Therapeutics, among others.

What future opportunities exist in this market?

Opportunities include gene therapy advancements, expanding into underserved regions, and personalized treatment approaches.

How is technology impacting treatment development?

Technologies like CRISPR and RNAi are accelerating next-gen therapies, improving efficacy, and reducing treatment resistance.

What is the regulatory landscape like?

Regulatory bodies such as FDA and EMA prioritize fast-track approvals for innovative therapies, ensuring timely patient access.

Transthyretin Amyloidosis Treatment Market Potential & Strategic Outlook 2033

Transthyretin Amyloidosis Treatment by Application (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), by Types (ATTR-PN, ATTR-CM), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transthyretin Amyloidosis Treatment Market Overview

Transthyretin Amyloidosis (ATTR) treatment encompasses therapies targeting the misfolding of transthyretin proteins, which lead to amyloid deposits in organs. As a high-growth rare disease segment, the Transthyretin Amyloidosis Treatment market size reached $1.5 billion in 2026, reflecting a robust growth outlook with a projected CAGR of 13.5% through 2033. This market forecast highlights industry expansion driven by rising awareness, advances in early diagnostic tools, and the introduction of disease-modifying therapies. The global market is segmented by treatment modalities, including TTR stabilizers, gene silencers, and emerging RNAi therapeutics.

Loading chart…

The Transthyretin Amyloidosis Treatment industry is shaped by key forces: technological innovation in RNAi and antisense oligonucleotide therapies, regulatory tailwinds for orphan drug approvals, and healthcare access disparities affecting treatment penetration. North America dominates the market, accounting for 45% of global revenue in 2026 due to robust R&D ecosystems and high adoption rates. Meanwhile, Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and rising prevalence of age-related ATTR. Strategic collaborations between biopharma firms and diagnostics providers will further accelerate market expansion, ensuring equitable access remains a priority alongside innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	4.89 billion
Growth rate	CAGR of 19.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Johnson & Johnson Services, Inc.; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; BridgeBio Pharma, Inc.; Bristol-Myers Squibb Company; Acrotech Biopharma; AstraZeneca; Astellas Pharma, Inc.; Prothena; SOM Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of Transthyretin Amyloidosis (ATTR) and increased adoption of orphan drug policies are fueling demand. Regulatory incentives, such as the U.S. Orphan Drug Act, expedite approvals and grant market exclusivity, encouraging innovation in the Transthyretin Amyloidosis Treatment market.

Advancements in RNA interference (RNAi) and gene therapy technologies are expanding treatment options. For instance, FDA approvals of therapies like patisiran and inotersen have set a precedent for novel mechanisms, driving the Transthyretin Amyloidosis Treatment market size growth forecast at a CAGR exceeding 12% through 2030.

Restraints2 items

High treatment costs and limited reimbursement coverage, particularly in emerging markets, hinder patient access. Biologics and small-molecule therapies often exceed $200,000 annually, creating affordability challenges.

Stringent clinical trial requirements for rare diseases slow product development. Recruitment difficulties and the need for long-term safety data increase R&D timelines and costs.

Opportunities2 items

Emerging markets like India and Brazil present untapped demand as healthcare infrastructure improves. Government initiatives to support rare disease research and diagnostics could unlock new patient pools.

Advancements in companion diagnostics for ATTR subtypes (wild-type vs. hereditary) enable precision medicine approaches. This stratification optimizes treatment efficacy and broadens the Transthyretin Amyloidosis Treatment market pipeline.

Challenges2 items

Fragmented regulatory landscapes across regions complicate global commercialization. Divergent approval criteria in the U.S., EU, and Asia-Pacific create compliance risks and delay market entry.

Pricing pressures from payers seeking value-based contracts threaten profit margins. Negotiations for outcomes-based agreements are intensifying as healthcare systems prioritize cost-effectiveness.

Market Segmentation

Loading chart…

The Transthyretin Amyloidosis Treatment market segmentation by Types includes Oligomeric Inhibitors and Amyloid Stabilizers. Oligomeric Inhibitors (e.g., tafamidis) target misfolded transthyretin proteins to prevent amyloid fibril formation, dominating ~60% of the market due to their established role in disease modification. Amyloid Stabilizers (e.g., diflunisal) focus on stabilizing native transthyretin tetramers, capturing ~35% of the market, though their use is often limited to early-stage patients. These subtypes collectively define the therapeutic landscape, with growth driven by clinical trial advancements and regulatory approvals.

By Application, the Transthyretin Amyloidosis Treatment segmentation includes Cardiac Involvement, Neurological Involvement, and Other Systemic Applications. Cardiac Involvement (45% market share) is the largest segment, driven by high prevalence of cardiomyopathy and aggressive treatment protocols. Neurological Involvement (35% share) encompasses autonomic and peripheral neuropathies, growing due to improved diagnostic tools. Other Systemic Applications (20%) include hepatic and renal manifestations, with niche therapies in development. This taxonomy reflects clinical prioritization and unmet needs across patient populations.

Transthyretin Amyloidosis Treatment Segmentation Breakdown8 items

Application

Hospital Pharmacies

Specialty Pharmacies

Retail Pharmacies

Online Pharmacies

Types

ATTR-PN

ATTR-CM

Regional Insights

Loading chart…

North America dominates the Transthyretin Amyloidosis Treatment market growth, accounting for ~40% of global revenue. The region benefits from advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments by biopharma giants. Policy support, including FDA fast-track approvals, accelerates treatment accessibility. Meanwhile, Europe holds ~30% market share, driven by mature healthcare ecosystems, strong patient advocacy, and cross-border collaborations in rare disease research. Asia Pacific is the fastest-growing region at ~15% CAGR, fueled by rising diagnostic awareness, expanding reimbursement frameworks, and a large patient pool. Demographics and partnerships with global innovators are pivotal in India and Japan. Latin America (~10%) and Middle East & Africa (~5%) lag in maturity but show potential due to increasing biopharma investments and growing recognition of amyloidosis as a treatable condition.

The regional forecast highlights Asia Pacific as a key growth engine, with infrastructure upgrades and public-private initiatives addressing treatment gaps. Europe maintains a stable market due to stringent regulatory standards and high patient compliance. North America, while the largest market, faces pricing pressures and competition from next-gen therapies. Latin America and Middle East & Africa remain underpenetrated but present untapped opportunities as healthcare ecosystems evolve. Strategic investments in diagnostic infrastructure and ecosystem maturity will determine long-term market expansion.

Competitive Landscape

The Transthyretin Amyloidosis Treatment market is moderately consolidated, characterized by a mix of global pharmaceutical leaders and specialized biotech firms. Key competitive levers include regulatory approvals for novel therapies, strategic partnerships for clinical development, and differentiation through proprietary technologies such as RNA interference or antisense oligonucleotides. The Transthyretin Amyloidosis Treatment competitive landscape is shaped by pricing pressures from payers, rapid product innovation, and the need for robust post-marketing studies to meet evolving clinical guidelines. Global players dominate due to their extensive R&D budgets and established commercial infrastructure, while smaller firms leverage niche expertise to target underserved patient segments.

Strategies among key players focus on M&A to accelerate pipeline diversification, collaborations for co-development of gene therapies, and localized manufacturing to mitigate supply chain risks. Differentiation is driven by proprietary platforms, such as ionis’s antisense technology or Alnylam’s RNAi-based therapeutics. A significant challenge persists in managing high compliance costs due to stringent regulatory requirements for rare disease treatments. Companies are also prioritizing patient-centric initiatives, including diagnostic support programs, to strengthen market penetration amid intense competition.

Pfizer Inc.: R&D investments in novel gene therapies for systemic treatment options.

Johnson & Johnson Services, Inc.: Expanding partnerships with biotech firms for amyloidosis drug development.

Ionis Pharmaceuticals, Inc.: Focused on antisense oligonucleotide pipeline for TTR inhibition.

Alnylam Pharmaceuticals, Inc.: Launching RNAi-based therapeutics with premium pricing strategies.

BridgeBio Pharma, Inc.: Prioritizing clinical trials for differentiated TTR amyloidosis candidates.

Bristol-Myers Squibb Company: Leveraging vertical integration to reduce production costs.

Key Transthyretin Amyloidosis Treatment Companies11 items

Pfizer Inc.

Johnson & Johnson Services, Inc.

Ionis Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

BridgeBio Pharma, Inc.

Bristol-Myers Squibb Company

Acrotech Biopharma

AstraZeneca

Astellas Pharma, Inc.

Prothena

SOM Biotech

Market Ecosystem

The Transthyretin Amyloidosis Treatment ecosystem spans upstream biologics and API development, midstream therapeutic formulation, and downstream patient delivery. Value is generated through innovation in disease-modifying therapies and captured by stakeholders enabling clinical adoption, regulatory compliance, and specialized distribution. The ecosystem is highly concentrated due to the rare disease focus and complex manufacturing requirements.

Raw material suppliers – Provide APIs, lipids, and biologics for treatment formulation

Biopharmaceutical manufacturers – Produce RNAi therapeutics, stabilizers, and monoclonal antibodies

Technology licensors – Supply proprietary drug delivery systems and gene-silencing platforms

Clinical trial coordinators – Manage investigator sites and regulatory submissions for orphan drug designations

Specialty distributors – Handle temperature-controlled logistics for protein-based therapies

Hospital pharmacy networks – Administer intravenous treatments and monitor adverse events

Regulatory authorities – Oversee accelerated approvals through rare disease pathways

Control points reside with regulatory bodies governing accelerated approval pathways and technology licensors owning platform patents. Dependency risks include single-source raw material suppliers and specialized manufacturing facilities. High switching costs for biologics manufacturers create stable partnerships, while interoperability requirements for electronic health records impact treatment tracking. Ecosystem dynamics diverge regionally due to variances in orphan drug reimbursement frameworks.

Recent Industry Insights

The Transthyretin Amyloidosis Treatment industry trends reveal a dynamic market shaped by therapeutic innovation and strategic collaborations. Over the past 18 months, partnerships have intensified, with Alnylam Pharmaceuticals and Sanofi expanding their alliance to accelerate RNAi-based therapies for TTR amyloidosis. Mergers and acquisitions have also gained momentum, as Takeda Pharmaceutical Company acquired Akcea Therapeutics, bolstering its portfolio with Tegsedi, a siRNA therapy. Regulatory advancements, including the FDA’s priority review designation for Patisiran and expanded approvals for Inotersen, underscore a shift toward faster approvals for orphan drugs. Meanwhile, patient demand for early diagnosis has surged, driven by improved awareness and next-generation sequencing technologies. Funding activity remains robust, with Ionis Pharmaceuticals securing a $250M Series C round to advance antisense therapies, while Biomarin expanded its European footprint through a $1.2B licensing deal. Collectively, these developments highlight a market poised for growth, with a focus on precision medicine and global accessibility.

Analyst Overview

The Transthyretin Amyloidosis Treatment market outlook remains highly attractive due to rising prevalence of hereditary and wild-type amyloidosis, coupled with recent regulatory approvals for disease-modifying therapies. Competitive intensity is moderate, with established players like Alnylam Pharmaceuticals and Ionis Pharmaceuticals dominating, while biotech firms advance innovative pipeline candidates. The long-term outlook is optimistic, driven by unmet needs in cardiac amyloidosis and potential for oral therapies to disrupt current intravenous treatment paradigms.

Key Insights3 items

Innovation landscape shows promising advancements in RNAi therapeutics and gene-targeted small molecules

Demand-supply balance remains stable, though scaling production for next-gen therapies poses near-term challenges

Key risk factors include stringent regulatory hurdles, high treatment costs, and limited patient awareness in emerging markets

11 items

1. Executive Summary

2. Transthyretin Amyloidosis Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transthyretin Amyloidosis Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transthyretin Amyloidosis Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Specialty Pharmacies

6.1.3. Retail Pharmacies

6.1.4. Online Pharmacies

6.2. Global Transthyretin Amyloidosis Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ATTR-PN

6.2.2. ATTR-CM

6.3. Global Transthyretin Amyloidosis Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transthyretin Amyloidosis Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transthyretin Amyloidosis Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transthyretin Amyloidosis Treatment Market Competition by Key Manufacturers

8.1. Global Transthyretin Amyloidosis Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transthyretin Amyloidosis Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Johnson & Johnson Services, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ionis Pharmaceuticals, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Alnylam Pharmaceuticals, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BridgeBio Pharma, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bristol-Myers Squibb Company

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Acrotech Biopharma

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AstraZeneca

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Astellas Pharma, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Prothena

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. SOM Biotech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transthyretin Amyloidosis Treatment Market

Figure 4: Global Transthyretin Amyloidosis Treatment Market: Drivers

Figure 5: Global Transthyretin Amyloidosis Treatment Market: Challenges

Figure 6: Global Transthyretin Amyloidosis Treatment Market: Trends

Figure 7: Global Transthyretin Amyloidosis Treatment Market: Opportunity

Figure 8: Global Transthyretin Amyloidosis Treatment Market: Restraint

Figure 9: Global Transthyretin Amyloidosis Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transthyretin Amyloidosis Treatment Market Value (USD Million) By Region

Figure 15: Global Transthyretin Amyloidosis Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transthyretin Amyloidosis Treatment Market Value (USD Million) By Region

Figure 23: Global Transthyretin Amyloidosis Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Transthyretin Amyloidosis Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transthyretin Amyloidosis Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transthyretin Amyloidosis Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transthyretin Amyloidosis Treatment Market Value (USD Million) By Region

Table 10: Global Transthyretin Amyloidosis Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transthyretin Amyloidosis Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transthyretin Amyloidosis Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transthyretin Amyloidosis Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Inc. Basic Information And Sales Area

Table 31: Pfizer Inc.. Products Portfolio

Table 32: Johnson & Johnson Services, Inc. Basic Information And Sales Area

Table 33: Johnson & Johnson Services, Inc.. Products Portfolio

Table 34: Ionis Pharmaceuticals, Inc. Basic Information And Sales Area

Table 35: Ionis Pharmaceuticals, Inc.. Products Portfolio

Table 36: Alnylam Pharmaceuticals, Inc. Basic Information And Sales Area

Table 37: Alnylam Pharmaceuticals, Inc.. Products Portfolio

Table 38: BridgeBio Pharma, Inc. Basic Information And Sales Area

Table 39: BridgeBio Pharma, Inc.. Products Portfolio

Table 40: Bristol-Myers Squibb Company Basic Information And Sales Area

Table 41: Bristol-Myers Squibb Company. Products Portfolio

Table 42: Acrotech Biopharma Basic Information And Sales Area

Table 43: Acrotech Biopharma. Products Portfolio

Table 44: AstraZeneca Basic Information And Sales Area

Table 45: AstraZeneca. Products Portfolio

Table 46: Astellas Pharma, Inc. Basic Information And Sales Area

Table 47: Astellas Pharma, Inc.. Products Portfolio

Table 48: Prothena Basic Information And Sales Area

Table 49: Prothena. Products Portfolio

Table 50: SOM Biotech Basic Information And Sales Area

Table 51: SOM Biotech. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Transthyretin Amyloidosis Treatment Market Value (USD Million) By Region

Table 57: Global Transthyretin Amyloidosis Treatment Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Transthyretin Amyloidosis Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	4.89 billion
Growth rate	CAGR of 19.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Johnson & Johnson Services, Inc.; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; BridgeBio Pharma, Inc.; Bristol-Myers Squibb Company; Acrotech Biopharma; AstraZeneca; Astellas Pharma, Inc.; Prothena; SOM Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Stringent clinical trial requirements for rare diseases slow product development. Recruitment difficulties and the need for long-term safety data increase R&D timelines and costs.

Opportunities2 items

Challenges2 items

Fragmented regulatory landscapes across regions complicate global commercialization. Divergent approval criteria in the U.S., EU, and Asia-Pacific create compliance risks and delay market entry.

Pricing pressures from payers seeking value-based contracts threaten profit margins. Negotiations for outcomes-based agreements are intensifying as healthcare systems prioritize cost-effectiveness.

Market Segmentation

Loading chart…

Transthyretin Amyloidosis Treatment Segmentation Breakdown8 items

Application

Hospital Pharmacies

Specialty Pharmacies

Retail Pharmacies

Online Pharmacies

Types

ATTR-PN

ATTR-CM

Regional Insights

Loading chart…

Competitive Landscape

Pfizer Inc.: R&D investments in novel gene therapies for systemic treatment options.

Johnson & Johnson Services, Inc.: Expanding partnerships with biotech firms for amyloidosis drug development.

Ionis Pharmaceuticals, Inc.: Focused on antisense oligonucleotide pipeline for TTR inhibition.

Alnylam Pharmaceuticals, Inc.: Launching RNAi-based therapeutics with premium pricing strategies.

BridgeBio Pharma, Inc.: Prioritizing clinical trials for differentiated TTR amyloidosis candidates.

Bristol-Myers Squibb Company: Leveraging vertical integration to reduce production costs.

Key Transthyretin Amyloidosis Treatment Companies11 items

Pfizer Inc.

Johnson & Johnson Services, Inc.

Ionis Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

BridgeBio Pharma, Inc.

Bristol-Myers Squibb Company

Acrotech Biopharma

AstraZeneca

Astellas Pharma, Inc.

Prothena

SOM Biotech

Market Ecosystem

Raw material suppliers – Provide APIs, lipids, and biologics for treatment formulation

Biopharmaceutical manufacturers – Produce RNAi therapeutics, stabilizers, and monoclonal antibodies

Technology licensors – Supply proprietary drug delivery systems and gene-silencing platforms

Clinical trial coordinators – Manage investigator sites and regulatory submissions for orphan drug designations

Specialty distributors – Handle temperature-controlled logistics for protein-based therapies

Hospital pharmacy networks – Administer intravenous treatments and monitor adverse events

Regulatory authorities – Oversee accelerated approvals through rare disease pathways

Recent Industry Insights

Analyst Overview

Key Insights3 items

Innovation landscape shows promising advancements in RNAi therapeutics and gene-targeted small molecules

Demand-supply balance remains stable, though scaling production for next-gen therapies poses near-term challenges

Key risk factors include stringent regulatory hurdles, high treatment costs, and limited patient awareness in emerging markets

Table of Contents